Redirecting B7-H3.CAR T Cells to Chemokines Expressed in Osteosarcoma Enhances Homing and Antitumor Activity in Preclinical Models
Our patient-based pipeline identified targets for chemokine receptor modification of CAR T cells targeting OS. CXCR2 and CXCR6 expression enhanced the homing and anti-OS activity of B7-H3.CAR T cells. These findings support clinical evaluation of CXCR-modified CAR T cells to improve adoptive cell therapy for patients with OS.
Authors
- Peter J. Chockley (ORCID: https://orcid.org/0000-0002-5181-2696)
- Aaron B. Ross (ORCID: https://orcid.org/0000-0002-0084-0806)
- Heather Sheppard (ORCID: https://orcid.org/0000-0002-9623-2812)
- Lindsay J. Talbot (ORCID: https://orcid.org/0000-0001-7409-9873)
- Alexandra Beckett (ORCID: https://orcid.org/0000-0001-9396-9504)
- Ashley Chabot
- Christopher DeRenzo (ORCID: https://orcid.org/0000-0001-6127-4601)
- Stephen M Gottschalk (ORCID: https://orcid.org/0000-0003-3991-7468)
- Andrew M. Fleming (ORCID: https://orcid.org/0000-0001-5421-9014)
- Jian Wang (ORCID: https://orcid.org/0000-0002-1902-1528)
- Phuong Nguyen (ORCID: https://orcid.org/0000-0003-3384-8246)
Institutions
- St. Jude Children's Research Hospital (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2024-08-05
- DOI
- https://doi.org/10.1158/1078-0432.ccr-23-3298
- Citations
- 25
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 7.06
Funders
- Assisi Foundation of Memphis
- Rally Foundation
- St. Jude Children's Research Hospital
- American Lebanese Syrian Associated Charities
- National Cancer Institute